SCHEMBL25181069

SCHEMBL25181069

Cn1cc(-c2cccc(Cl)c2)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
CYP2C9 P11712 2/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
ESR2 Q92731 1/20 0.45
DCLRE1B Q9H816 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
KDM4C Q9H3R0 1/20 0.43
PIN1 Q13526 1/20 0.43
KMO O15229 2/20 0.42
IDO1 P14902 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA4 P48058 1/20 0.42
BRD4 O60885 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1126815 0.83 BRD4 (0.58) KDM4EALDH1A1GAACYP2C9MEN1
SCHEMBL1126651 0.78 CNR1 (0.45) KDM4EALDH1A1GAARXRARXRB
SCHEMBL11331078 0.76 CYP2C9 (0.64) ALDH1A1CYP2C9MEN1POLBKMT2A
SCHEMBL1277680 0.74 KMT2A (0.53) KDM4ECYP2C9MEN1POLBKMT2A
SCHEMBL11463699 0.74 CYP2C9 (0.45) KDM4EALDH1A1CYP2C9MEN1POLB
SCHEMBL12582221 0.73 CCNC (0.49) KDM4EALDH1A1GAACYP2C9MEN1
SCHEMBL16691879 0.73 CCNC (0.45) CYP2C9MEN1POLBKMT2ARXRA
SCHEMBL10958055 0.73 KMO (0.50) KDM4EMEN1POLBKMT2AKDM4C
SCHEMBL14800212 0.73 MEN1 (0.47) KDM4EALDH1A1CYP2C9MEN1POLB
SCHEMBL16115664 0.72 CCNC (0.73) KDM4EALDH1A1CYP2C9MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-11-13 US disclosed
EP-4431505-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2024-09-18 EP disclosed
CN-118234721-A Isoindolinone derivative with glutarimide mother nucleus and application thereof 韩国化学研究院 2024-06-21 CN disclosed
WO-2023085785-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF 한국화학연구원 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346575-A1 ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF CRBN, IDH1, IDH2 KDM4E 2129/4885ALDH1A1 849/4885GAA 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.